Journal ArticleDOI
The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas.
Richard Simon,Sylvain Durrleman,Richard T. Hoppe,Gianni Bonadonna,Clara D. Bloomfield,Richard A. Rudders,Bruce D. Cheson,Costan W. Berard +7 more
Reads0
Chats0
TLDR
The probability of long-term survival for unselected patients with non-Hodgkin lymphoma can be substantial and depends on the histologic subtype of the tumor and the extent of dissemination.Abstract:
STUDY OBJECTIVE To document the long-term prognosis of patients with non-Hodgkin lymphoma treated between 1971 and 1975 and to determine how the prognosis varies by histologic subtype and stage. SETTING Three cancer referral centers in the United States and one center in Italy. PATIENTS A consecutive sample of 1153 previously untreated patients with non-Hodgkin lymphoma. At the time of analysis, 71% of the patients had died and the median follow-up for patients still alive was 11.2 years. MEASUREMENTS AND MAIN RESULTS The 10-year survival proportions were 45% (CI, 40% to 50%); 26% (CI, 22% to 30%); and 23% (CI, 18% to 30%) for patients with low-, intermediate-, and high-grade lymphomas, respectively. Patients with intermediate- and high-grade lymphomas were curable, but this was not apparent for patients with advanced stage low-grade lymphomas. For the low-grade follicular small cleaved and follicular mixed lymphomas, the Ann Arbor staging system distinguished the prognosis of patients with stage I disease from those with more extensive involvement. For the diffuse large cell and immunoblastic lymphomas, the Ann Arbor staging system distinguished long-term prognosis for patients with stage I disease from patients with stage II disease and those with more disseminated involvement. CONCLUSIONS The probability of long-term survival for unselected patients with non-Hodgkin lymphoma can be substantial. Long-term prognosis depends on the histologic subtype of the tumor and the extent of dissemination. The Working Formulation for non-Hodgkin lymphomas is a simple and useful nomenclature for selecting treatment and reporting results. The Ann Arbor staging system is a useful but imperfect prognostic indicator.read more
Citations
More filters
Journal ArticleDOI
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.
Thomas P. Miller,Thomas M. Grogan,William S. Dalton,Catherine M. Spier,Rik J. Scheper,Sydney E. Salmon +5 more
TL;DR: It is concluded that the P-glycoprotein is uncommonly expressed in untreated lymphomas and frequently expressed in clinically drug-resistant disease, and that chemotherapy using CVAD plus maximally tolerated doses of verapamil results in a high response rate in patients carefully selected for clinical drug resistance.
Journal ArticleDOI
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma
Kenneth Offit,Francesco Lo Coco,Francesco Lo Coco,Diane C. Louie,Nasser Z. Parsa,Denis H. Y. Leung,Carol S. Portlock,Bihui H. Ye,Florigio Lista,Daniel A. Filippa,Ayala Rosenbaum,Marc Ladanyi,Suresh C. Jhanwar,Riccardo Dalla-Favera,R.S.K. Chaganti +14 more
TL;DR: Rearrangement of the bcl-6 gene correlated with a favorable clinical outcome in DLLC and may thus serve as a prognostic marker in patients with this form of malignant lymphoma.
Journal ArticleDOI
Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
B. Coiffier,Nicole Brousse,M. Peuchmaur,Françoise Berger,Christian Gisselbrecht,P. A. Bryon,Jacques Diebold +6 more
TL;DR: It is shown that peripheral T-cell MLs are associated with a poor prognosis and that the phenotype is independent of other adverse prognostic factors, along with LDH level, serum albumin level, and number of extranodal sites.
Journal ArticleDOI
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor
Jean-Yves Blay,N Burdin,Franpoise Rousset,Gilbert M. Lenoir,Pierre Biron,T Philip,Jacques Banchereau,M. Favrot +7 more
TL;DR: It is indicated that IL-10 is detectable in a subgroup of patients with active NHL and correlates to a poor survival in patients with intermediate or high-grade NHL.
Journal ArticleDOI
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Bertrand Coiffier,Christion Gisselbrecht,Julie M. Vose,Hervé Tilly,Raoul Herbrecht,André Bosly,James O. Armitage +6 more
TL;DR: In patients with aggressive lymphomas, this simple prognostic index could distinguish between patients requiring intensive treatment such as autologous bone marrow transplantation in first complete remission and those who could be treated with standard regimens.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.
Paul Klimo,Joseph M. Connors +1 more
TL;DR: MACOP-B is an effective treatment for large-cell lymphoma that can be delivered in 12 weeks with an acceptable incidence of toxicity and may be superior to other presently used regimens of longer duration.
Journal ArticleDOI
Non‐hodgkin's lymphomas iv. clinicopathologic correlation in 405 cases
Stephen E. Jones,Zvi Fuks,Malcolm Bull,Marshall E. Kadin,Ronald F. Dorfman,Henry S. Kaplan,Saul A. Rosenberg,Hun Kim +7 more
TL;DR: It is concluded that histopathologic classification proposed by Rappaport et al. and the Ann Arbor Staging Classification are both useful guides to the management and prognosis of the non‐Hodgkin's lymphomas.
Journal ArticleDOI
Confidence Intervals for Reporting Results of Clinical Trials
TL;DR: Confidence intervals are important but underused supplements to tests of significance for reporting the results of clinical investigations, and formulas are presented for calculating confidence intervals with types of data commonly found in clinical trials.
Journal ArticleDOI
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
Arthur T. Skarin,George P. Canellos,David S. Rosenthal,Delvyn C. Case,John M. Macintyre,Geraldine S. Pinkus,William C. Moloney,Emil Frei +7 more
TL;DR: M-BACOD results in prolonged survival and possible cure in a high proportion of all patients with DHL and DUL, and patients with prior therapy had a significantly lower CR rate than those without prior treatment.
Related Papers (5)
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more